Lille (France), Cambridge (Massachusetts, USA), Zurich (Switzerland), April 25, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company committed to improving the lives of...
Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 5, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the...
Cash and cash equivalents totaled ‚77.8 million as of December 31, 2023Revenues amounted to ‚28.6 million as of December 31, 2023 including a milestone payment of ‚13.3 millionTopline interim data for...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the...
US Food and Drug Administration (FDA) has granted Priority Review for New Drug Application (NDA) for elafibranor in PBC, and European Medicine Agency (EMA) has also validated the Marketing...
The paper published in Journal of Hepatology demonstrates that NIS2+„¢ technology could significantly reduce liver biopsy failure rate and maximizes accuracy of patient selection for MASH1 clinical...
GENFIT highlighted new focus and development strategy in Acute On-Chronic Liver Failure (ACLF)ACLF is a very serious condition affecting ~294,0001 2 patients with chronic liver diseases in the USA and...
ELATIVE® Phase III trial confirms potential for investigational elafibranor as a novel, first-in-class, dual PPAR α,δ agonist for patients with primary biliary cholangitis.Elafibranor demonstrates...
GENFIT to lead 3 key events on ACLF during AASLD: ACLF Day for Investors/Analysts on November 11, 2023Patient Advocacy Council meeting on November 11, 2023ACLF Investigator event on November 12,...